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ABSTRACT
Drug abuse disorders and addictive behaviors are serious public health problems and major contributors to the global
burden of disease. Previous studies show that N-acetylcysteine (NAC) may be involved in neurodevelopment adult
brain. The potential neuroprotective effect of NACis associated with modulate several neurological pathways,
including prevention of oxidative stress or inflammation damage to nervous tissue and glutamate dysregulation, NAC
is being explored as an adjunctive therapy for drug addiction and addiction management.We here review the role of
NAC in the addiction, such as cannabis abuse, methamphetamine abuse, cocaine addiction, nicotine dependency, and
gambling.Adequate administrate of NAC seems to be crucial in terms of addiction management. NAC is safe and well
tolerated when administered orally but has documented risks with intravenous administration. An evidence study
supports its use as an adjunctive therapy clinically for drug addiction, administered concomitantly with existing
medications. The aim of this review is to assess the current knowledge related to the role of NAC administration on
drug addiction and addiction management.
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INTRODUCTION
Substance abuse and drug addiction are a
chronically relapsing disturbance that has been
characterized by the compulsive use of addictive
substances despite side effects consequences to the
community and common people(1). Drug addiction
represents a significant and pressing public health
concern; also, lost productivity and drug-related
crime total about $621 billion per year in US(2).
Drug abuse is a major social and public health
difficulty and one of the top ranking risk factors for
other health conditions in Iran(3). Opioid abuse
disturbance were the most common form of illicit
drug use disorder in Iran. The types of opioids used
by subjects with a diagnosis of opioid abuse disorder
were opioid (82.3%), smoked opium ashes (“shireh”)
(27.8%), methadone (not medical usages) (16.6%),
heroin/crack of heroin (16.1%), and morphine
(2.6%). The percentages add up to more than 100%
because some individuals used more than one type
of opioid. Cannabis and amphetamine-type
stimulants abuse disorders were less common than
opioid abuse. The use of hallucinogens and cocaine
was rare(4). Opioid markets increase illegal careers
and negatively affect the resources available in legal
economies. Illegal opioid markets are also linked to
rises in crime and social insecurity(5). Addiction to
alcohol, drugs and cigarette smoking is now
regarded as a major public health problem. Other
forms of addiction including gambling, computer
games, food and sex also have severe consequences
on the health of the subjects and to society(6).The
National Institute of Health and Clinical Excellence
(NICE) recommends both methadone and
buprenorphine as a first line treatment for both
medically assisted withdrawal syndrome from types
of opiates and for maintenance treatment purposes,
with due consideration given to service user
preference. Guidelines protocols for management of
opioid abuse adopt similar recommendations, that
is, both methadone and buprenorphine as
pharmacotherapy(7). Despite methadone
maintenance treatment (MMT) and buprenorphine
maintenance treatment (BMT) programs being one of
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the most important treatment strategies for reducing
individual and public harms associated with opioid
use, a large proportion of Iranian patients refuse to
participate in such treatment programs(8). MMT and
BMT are the most frequently used opioid therapy. It is
readily available for patients seeking opioid
treatment in many countries. Evidence studies has
demonstrated that MMT and BMT has the capacity to
reduce the need to drug abuse, reduced the adverse
health effects of opioid use, such as fatal and
nonfatal drug overdoses, and keep patients in
maintenance treatment and decrease the risk of
relapse and withdrawal syndrome to drug use. Also,
MMT and BMT seems to improve HIV outcomes,
decrease hepatitis and HIV transmission, control
disturbance behaviors, and suppress criminal
activities such as drug dealing(7-10).Generally, MMT
and BMT improve social functioning and quality of
life(11). However, despite the extensive and
successful implementation of the MMT, many
challenges and obstacles remain. Recent evidence
demonstrated that NAC is vital for mental health and
central nervous system function. Grant et al.(12),
showed NAC plus naltrexone intake for 8-week in
subjects with metamphetamine addiction was
associated with a significant improved in craving and
withdrawal syndrome. In addition, results of a
systematic review reported that supplementation with
NAC had beneficial impact on treatment of
addiction, especially of cocaine and cannabis
dependence(13). Studies that have evaluated the role
of NAC on drug addiction are common. The aim of
this review is to assess the current knowledge related
to the role of NAC on addiction management.
Neurologicalstatus in substance abuse
Drug addiction can be described as a disturbance
which involves the neurological pathways of the
structure and neuronal brain. Evidence studies have
demonstrated that addiction can be alter the neural
circuitries that are involved in psychological
parameters (depression, anxiety, sleep, and sexual
function), decision making, cognitive function,
reward pathways, and memory. These regions are
important in reward related processes and drug
abuse, including anterior cingulate gyrus,
orbitofrontal cortex, mesocortical systems, ventral
tegmental area, nucleus accumbens, and cortex(14-
16). In human imaging studies, decreases in
dopaminergic function have been identified as a key
common element of addiction, lending support to
what became a strong program on the role of
dopamine in addiction(17). In addition, to the
mesocorticolimbic dopamine system,
specificcomponents of the basal forebrain have more
recently been identified with the
hedonicneuroadaptations to acute drug reward. As
the neural circuits for the reinforcing effects of drug
abusehave evolved, the role of neurotransmitters also
has evolved includingGABA, serotonin, opioid
peptide, and mesolimbic dopamine(18-20). Also,
changes in neurotransmitters and neurochemical
level occur in drug addiction include decreased
GABAergic, increased NMDA and glutamatergic
transmission, decreases in dopaminergic and
serotonergic transmission, increased sensitivity of
opioid receptor transduction during alcohol and
opiate withdrawal(20, 21). Reported studies from
brain imaging have shown an enhanced in opioid
receptors density in patients with alcohol, opioids,
and cocaine dependence(22-24). Evidence studies
have also demonstrated that the corticostriatal
glutamate pathway may be important in the initiation
and expression of a number of addictive behaviors
including conditioned place preference (CPP), drug
seeking and locomotor sensitization(25). in other
hand, the roles neuropeptides in drug abuse related
behaviors have been demonstrated; and for the most
part, neuropeptides including endogenous opioids,
signaling molecules like substance P, and
neuropeptide Y have been studied extensively as
possible therapeutic targets for addiction
management(14). The overall, although a number of
neuropeptides, neurotransmitters and
neuromodulators are involved in the reinforcing
impacts of addictive drugs; the dopaminergic reward
systems are central to the reinforcing properties of
drug abuse and the initiation of addiction(14, 26,
27). However, other mediators are believed to exert
their influence via dopamine pathway modulation.
N-acetylcysteine (NAC)
NAC, as a safe and inexpensive medication, is
commercially accessible since long-time ago. NAC is
a metabolite of the sulphur containing amino acid
cysteine. It has the molecular formula
HSCH2CH(NHCOCH3)CO2H and formula weight
163.19(28, 29). NAC exerts survival-promoting
effects in several cellular systems(30). Cysteine is
transported mainly by the ASC system, a ubiquitous
system of Na+ dependent neutral amino acid
transport in a variety of cells(31). However, NAC is a
membrane-permeable cysteine precursor that does
not require active transport. After free NAC enters a
cell, it is rapidly hydrolyzed to release cysteine, a
precursor of GSH(32).The mechanism of action of
NAC and consequently its dosing varies with
indication(28). Nausea, vomiting and diarrhea have
been demonstrated as dose-dependent adverse
effects of oral NAC(33). Oral bioavailability of NAC
is estimated at 6 – 10%, due to extensive first-pass
metabolism, with Tmax at 1 – 2 h. The volume of
distribution ranges from 0.33 to 0.47 l/kg(34, 35).
Taking NAC has been demonstrated to increase
available GSH. After free NAC enters a cell, it is
rapidly hydrolyzed to release cysteine, a precursor of
GSH. GSH is synthesized by the coactions of c-
glutamylcysteinesynthetase and GSH synthetase(36-
38). GSH participates enzymatically and non-
enzymatically in protection against oxidative stress
damage caused by Reactive Oxygen Species. In
addition, GSH peroxidase catalyzes the destruction of
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hydroperoxides and H2O2(36). Therefore,
supplementation with NAC is an antioxidant and a
free-radical scavenging agent that increases GSH,
and prevention from oxidative stress(39). Also, NAC
has been demonstrated to have anti-inflammatory
properties. In addition, NACis inhibited induction of
the pro-inflammatory transcription factors NF- κB
and AP-1. These transcription factors have been
found to be induced in response to oxidative stress,
supporting the argument that the anti-inflammatory
properties of NAC are due to its mechanism of action
as an antioxidant(40). Treatment with NAC has been
shown for several illnesses including acetominophen
poisoning(41), pulmonary diseases(42), addictive
behaviors(43, 44), psychiatric illnesses(45, 46),
neurological diseases(47, 48), and infectious
diseases(49, 50). The current evidence supporting
NAC for treating substance use disorders(51).
Dosages of NAC suggested for the treatment of
stimulation disorder including cocaine, range from
1,200 to 3,600 mg/d, with higher retention rates
noted in subjects who received 2,400 or 3,600
mg/d(52). NAC is to act as an anti-relapse agent,
rather than an agent that can help someone who is
actively using stimulants to stop. Also, NAC will likely
be most helpful for individuals who are motivated to
quit and are abstinent when they start consuming
NAC (51).
NAC and methamphetamine abuse
Methamphetamine (MA) abuse is a growing social
problem all over the world. MA abuse is a new
health concern in the Iranian population(53). MA first
appeared in 2005, initially and illegally imported
from South-east Asia. The prevalence of MA
dependence is less than one percent in the general
population of Iran. Research findings demonstrated
that recent years, the MA abuse increased from 3.9%
to 89.5% among women and 60.3% among men in
Iran(54). Also, studies indicated that the prevalence
of MA in Iran during recent years has risen among
patients under MMT(54, 55). The psychiatric effects
of MA use are problems such as increased craving,
cognitive impairment, depression and anxiety
symptoms and sleep disturbances, and withdrawal
syndrome accompany acute withdrawal from MA(56-
63). Recently, various psychosocial interventions
including technology-based treatments, matrix model
and cognitive- behavioural therapy have been
employed in the treatment of patients with MA
dependence(64-66). Chronic and severe MA abuse
is associated with deep alterations in brain circuits,
which results in severe craving for the substance.
Thus, the use of an effective pharmacotherapy that
could reduce craving is an important goal of
treatment of addiction. Pharmacotherapy might
provide some benefit, but there is disagreement
about the potential benefits of various
pharmacologic agents for the treatment of drug
abuse. The beneficial effect of NAC for the treatment
of drug abuse has been demonstrated in patients
with MA dependence. Previous studies demonstrated
that NAC may have the beneficial effects on craving
and withdrawal. In the study by Mousaviet al.(67), it
was documented that consuming 600 mg/day to a
maximum of 1200 mg/day NAC for two four-week
in patients with MA dependence disorders had
favorable effects on craving scale.In commentary
studies demonstrated that administration of NACmay
be helpful in managing signs of dependence that
develop with heavy MA use including craving and
relapse(68). In addition, in a meta-analysis
conducted by Duailibi et al.(69), NAC intakes were
linked into craving reduction in substance use
disorders including MA abuse. However, in another
study NAC supplementation showed no signiﬁcant
effect on craving symptoms or MA use in MA-
dependent(12). NAC, a cysteine pro-drug, is involved
in restoring glutamate concentrations (enhancing
activation of the mGluR2/3 receptors) in the nucleus
accumbens, which would be linked to craving signs,
and relapse(70-73). In addition, effects of NAC
intake might mediated by antioxidant effects. NAC
serves as a source of cysteine, which can promote
glutamate exchange through the cysteine glutamate
in glial cells. Cysteine would then enhance cellular
production of GSH, which is an intracellular
antioxidant, preventing cellular damage from
ROS(69, 74).
NAC and cannabis abuse
Marijuana is the most commonly used illicit
substance in the world .Consumed by an estimated
2.5% of the world’s population and rates of abuse
continue to enhance(75). Cannabis abuse has
become increasingly popular in Iranian cities
according to various reports(76, 77). Cannabis is
used in Iran in both the form of grass (marijuana)
and hashish. Whereasthe public perception of risks is
diminishing; cannabis abuse is linked to substantial
health-related impacts and disturbance(78,
79).Evidence studies demonstrated lifetime history of
cannabis abuse at 0.2% in secondary school boys
aged 12–14 and 8.2% for high school boys aged
15–17. The Zanjan study showed a 2.8% lifetime use
of cannabis in high school students. The rate was
5.7% among boys, and none of girls had history of
cannabis use(80). There is evidence that substance
abuse in Iran and other countries have greater
psychological dysfunction(81, 82).Depending on age
of onset, frequency, duration, and other variables,
cannabis use can be associated with a broad
spectrum of medical consequences, the range of
which mirrors the physiological ubiquity and
versatility of the endo-cannabinoid system(83).
Experimentalevidence has showndys-regulation in
glutamatergicpathway within a prefrontal cortex-
nucleus accumbensfollowing periods of self-
administration and withdrawal syndrome across
multiple drug abuse(25, 84, 85). These
reporteddemonstrated that glutamate plays a key
role in substance abuse and reinstatement models,
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suggesting that glutamate is a promising
neurochemical target for medication development to
treat drug abuse(86, 87). Also, an evidence study
suggests that cannabinoid intake disrupts normal
glutamate functioning, and disinhibits dopamine
transmission(88-90). Among glutamate-targeted
pharmacotherapies for illicit drug, NAC has emerged
as a particularly strong candidate(86, 87). Therefore,
supplementation of NAC can be the favorable effects
on cannabis abuse. In the study by McClure et
al.(91), it was documented that 1200 mg/twice-daily
orally-administered NAC for 12-week among
cannabis users in any age group had favorable
effects on increased odds of abstinence.Also, after
NAC intake for 8 weeks, compared to placebo more
than doubled the odds of abstinence during
treatment, reflected in negative weekly urine
cannabinoid tests in adolescents ages with cannabis
abuse(92). However, in another study byGray et
al.(93),there is no evidence that NAC 1200
mg/twice-daily plus contingency management is
differentially efficacious for cannabis use disorder in
adults when compared to placebo plus contingency
management. NAC is pro-drug and stimulates
cystine-glutamate and increasing non-synaptic glial
release of glutamate(94). So, NAC has also been
demonstrated to decrease the reinstatement of drug-
seeking in animal evidence across mix-users
substances (94-97).
NAC and cocaine addiction
Cocaine is a tropane ester alkaloid found in leaves
of the Erythroxylum coca plant, a bush that grows in
the Andes Mountain region of South America.
Cocaine abuse can lead to addiction and side
effects, such as cardiac arrest and stroke(98). The
rate reported by the United Nations Office on Drugs
and Crime in the year of 2017 for the whole world
population was of 0.35%(99). In Iran abuse of
cocaine, hallucinogens and inhalants was rare(4).
Several mechanisms have been demonstrated for
cocaine neuro-toxicity, including oxidative stress
alterations. NF-κB, considered a sensor of
inflammation and oxidative stress, is involved in drug
abuse and addiction. NF-κB is a key mediator for
immune responses that induces
microglial/macrophage activation under
inflammatory parameters and neuronal
injury/degeneration. Cocaine exposure linked to up-
regulation of pro-inflammatory mediators such as
cytokines and chemokines, or astroglia/microglia
activation(100-103). In addition, evidence studies
has demonstrated that following chronic cocaine
abuse, basal extracellular glutamate status within the
nucleus accumbens are decreased, which linked to
the reinstatement of cocaine-seeking behaviors in
animal models of relapse(71, 104). NAC, a cysteine
pro-drug and amino acid, appears to restore basal
status of glutamate in the accumbens, leading to a
marked decreased in cocaine-seeking behavior after
a cocaine challenge(105). In clinical trials
demonstrated that subjects NAC supplementation
decreased cocaine abuse for one month.
Importantly, clinical studies thus far have found NAC
to be safe and well-tolerated among cocaine-
dependent subjects(52, 106). A previous systematic
review of NAC was superior to placebo for craving
reduction in substance use disorders including
methamphetamine, cannabis, cocaine, and
nicotine(69). LaRowe et al.(107), showed that
administration NAC at a dosage of 1200 mg and
2400 mg/daily for 8 weeks had beneficial effects on
reduces cocaine use in cocaine-dependent subjects
actively using. Also, taking NAC supplementation for
three-day by cocaine-dependent humans had
beneficial effects on reduces cocaine-related
withdrawal symptoms and craving(106). However,
there is a growing body of evidence indicating that
NAC is not only potentially useful as a treatment for
cocaine dependence(43, 108). So, further clinical
trials for assessing the efficacy of NAC on cocaine
dependence are warranted. The accurate mechanism
of effect of NAC on craving reduction is not
completely understood.Importantly, NAC have been
found to have beneficial effects on enhance in
glutamate status, stimulating inhibitory presynaptic
mGluR2/3 receptors,and stimulating excitatory
postsynaptic mGluR5 receptors (109-112).
NAC and nicotine abuse
There are 1.1 billion people smokers in the world,
almost 80% of who reside in developing countries.
With 26 countries now considered to be in active
conflict or in the post-conflict setting(113), some 1.5
billion people are living in high exposure risk
worldwide(114). In Iraq, smoking prevalence
estimates are estimated to be 31% and 4% for males
and females, respectively(115). Iran still has good
tobacco control measures in place and prevalence
has remained fairly stable, with 20% of males and 2–
3% of females smoking daily(116, 117). WHO
reported the prevalence of cigarette consumption in
Iran to be 22 % among adult men and 1% among
women in 2010. Furthermore, they estimated that
these figures would reach 19% among men and 10%
among women in 2025.Nine percent of the total
population in Iran was anticipated to be smokers in
2025(118, 119). WHO also estimates that smoking
(cigarette and smoke) is currently responsible for
death of 6 million people worldwide, of which many
are premature deaths(119). And a third of all cancer
deaths are associated with smoking(120, 121). Most
cigarette smoking try to quit smoking without
professional assistance, though there is evidence
studies that pharmacologically supported
interventions are effective in the prevention of relapse
and withdrawal symptoms including bupropion or
varenicline(122, 123). Nicotine stimulates nicotine
acetylcholine receptors in the CNS, which in turn
elevate the release of several neurotransmitters (i.e.,
glutamate, dopamine, serotonin and GABA).
Treatment strategies have focused on ACh receptors
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or blocking the reuptake of noradrenaline and
dopamine including bupropion or varenicline(124-
129). Despite the relative effectiveness of current
first-line medications for promoting smoking
abstinence, most quit attempts result in relapse.
Recently, the role of glutamate transmission in drug
abuse dependence has been more extensively
investigated. Preclinical evidence studies have
emerged for the involvement of glutamate in relapse
and withdrawal symptom(73, 130).In animal studies,
chronic nicotine exposure is demonstrated to
disturbance functioning of the glial glutamate
transporter (GLT-1) in the nucleus accumbens.
Disturbance GLT-1 function reduce the rate of
glutamate elimination, thereby augmenting the
spillover of synaptically-released glutamate during
reinstated drug seeking(70, 131, 132). Also, synaptic
glutamate transmission mediates the primary
reinforcing effects of nicotine in animal models:
stimulating mGluR2/3 receptors, inhibits synaptic
glutamate release, and decrease the rewarding
effects of nicotine. However, enhancing extracellular
glutamate attenuates symptoms linked to nicotine
withdrawal(133, 134). NAC, a cysteine pro-drug that
regulates cellular glutamate, holds promise as a
medication to normalize frontostriatal function or
prevent relapse and withdrawal symptom. NAC
exerts antioxidant properties with activation of the
cystine-glutamate exchanger(135, 136). Few studies
have assessed the effects of NAC administration on
nicotine dependence. Schmaalet al.(137), showed
that administration NAC at a dosage of 3600
mg/day for 4 days had beneficial effects on
withdrawal symptoms in patients with nicotine
dependence, but there was no significant effect on
craving. The results of this pilot study are suggested
that NAC may be a promising new treatment option
for relapse prevention in nicotine dependence. In an
animal and human study by Knackstedt et al.(97), it
was seen observed that the administration of NAC
reduced xCT expression in the nucleus accumbens
and VTA, and decreased GLT-1 expression in the
nucleus accumbens rats. Also, in this study reported
a reduction in cigarettes smoked, and there was no
effect on estimates of CO levels, craving, or
withdrawal in human smokers. In addition, taking
NACsupplementation may positively affect potentially
dys regulated corticostriatal connectivity, help to
maintain abstinence immediately and restructure
reward processing(138). However, more clinical trial
studies are needed to evaluate its potential clinical
effect in cigarette smoking. NAC activates system xc-
and enhances intracellular glutathione synthesis and
releases glutamate. Also, supplementation with NAC
is increasing system xc- activity in smokers. Such a
restoration of xc- activity may underlie the improved
success by the NAC treated individuals in resisting
cigarette smoking (71, 94, 96).
NAC and pathological gambling
Worldwide, concern has grown over the expansion of
gambling among adolescents, who have an
enhanced likelihood of developing risk-taking
behaviors(139). Past-year adult prevalence rates for
pathological gambling are estimated at 1%.
Although pathological gambling occurs frequently in
primary care, it often goes unrecognized and
untreated. Because untreated pathological gambling
can disturbance function in multiple domains,
validated treatments are needed to optimize mental
health care(140-142). Gambling practices and
opportunities have evolved to the point where they
are widely available and viewed as a socially
acceptable form of entertainment, while becoming
increasingly attractive to young people including
mobile gambling, online gambling, social casino
gambling, gambling within online video games, and
simulated gambling within other forms of
entertainment(143-145). The severe gambling
problems may meet criteria for pathological
gambling, a diagnostic entity introduced in the
Diagnostic and Statistical Manual. Several
neurochemical systems have been implicated in
gambling. Adrenergic systems have been linked to
excitement, serotonin to impulse control, dopamine
to rewarding and reinforcing aspects, opioids to
euphoria, cortisol to stress responsiveness, and
glutamate to cognitive functioning.In addition, many
neurotransmitter systems including norepinephrine,
serotonin, dopamine, opioid and glutamate and
brain regions such as ventral striatum, ventromedial
prefrontal cortex, insula, have been implicated in
gambling(146-148). Furthermore, pathological
gambling is linked to elevated nicotine dependence,
and tobacco smoking in pathological gamblers has
been associated with enhanced problem-gambling
severity(149). Evidence of pre-clinical studies
hasdemonstrated that status of glutamate within the
nucleus accumbens mediate reward seeking
behavior(72, 73, 150, 151). NAC has demonstrated
the beneficial benefit of on reducing the reward-
seeking behavior, by enhanced status of glutamate,
stimulate inhibitory metabotropic glutamate
receptors, and reduce synaptic release of
glutamate(70).The results of the study showed that
Grant et al.(149), a significant benefit of NAC
treatment on nicotine dependence total scores. Also,
during the 3-month follow-up, there was a significant
benefit for NAC versus placebo on measures of
problem-gambling severity. So, NAC treatment
during therapy facilitates long-term application of
behavioral therapy techniques once individuals are in
the community after therapy has been completed.In
addition, Grant et al.(44), showed that 600mg/day
and increased to 1200 mg/day NAC
supplementation for 8 weeks was linked into a
significant improve in reward-seeking addictive
behaviors such as gambling.NAC seems to
enhanced the activity of cysteine-glutamate
antiporters in the nucleus accumbens and abolishes
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the reward-seeking behavior(72, 73). Therefore, the
studies longer, and placebo-controlled double-blind
studies are needed.
Conclusion
The supplementation of NAC has been studied in
several drug abuse disorders and seems to be a
novel treatment approach. Data is still limited, but
overall the effect trends in a positive direction for
many drug abuse including cannabis abuse,
methamphetamine abuse, cocaine addiction,
nicotine dependency, and gambling. NAC
supplementation appears effective, affordable, safe,
and tolerable. Long-term interventions and larger
clinical trials are needed for addiction management.
Prospective studies are needed to evaluate the
eligibility of NAC in addiction management and drug
abuse.
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